Restenosis - Pipeline Review, H1 2019

Publication ID: GMD0319007
Publication Date: March 18, 2019
Pages: 48
Publisher: Global Markets Direct
Region: Global

$2,000.00

Publication License Type *
- Single User License (PDF), $2,000.00
- Site License (PDF), $4,000.00
- Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Description:
Restenosis - Pipeline Review, H1 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Restenosis - Pipeline Review, H1 2019, provides an overview of the Restenosis (Cardiovascular) pipeline landscape.

Restenosis is re-narrowing of a blood vessel which leads to restricted blood flow. Symptoms include shortness of breath, difficulty walking and chest pain. Risk factors include increasing age, gender, family history or race and diabetes. Treatment includes surgery and thrombolytic therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Restenosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Restenosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restenosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Restenosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Restenosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Restenosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Restenosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Restenosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Restenosis (Cardiovascular)

**Reasons to buy**

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Restenosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Restenosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Contents:**

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restenosis - Overview
Restenosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Restenosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Restenosis - Companies Involved in Therapeutics Development
CytoTools AG
XBiotech Inc
Restenosis - Drug Profiles
(connective tissue growth factor + insulin human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bermekimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMW-02Ak - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMW-02Ap - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TW-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Restenosis - Dormant Projects
Restenosis - Discontinued Products
Restenosis - Product Development Milestones
Featured News & Press Releases
Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal
Antibody Therapy Targeting Inflammatory Cytokine IL-1α For Restenosis

Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease

Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites

Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Restenosis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Restenosis - Pipeline by CytoTools AG, H1 2019
Restenosis - Pipeline by XBiotech Inc, H1 2019
Restenosis - Dormant Projects, H1 2019
Restenosis - Dormant Projects, H1 2019 (Contd..1), H1 2019
Restenosis - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Restenosis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Mentioned:
CytoTools AG
XBiotech Inc

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or
persons outside of the organization.

- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Drug Pipeline

No. 1101, Golden Square, 3rd Floor, 24th Main, J P Nagar, 1st Phase, Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

About Us
Reports by Region
FAQ
Privacy Policy
TERMS & CONDITIONS
CONTACT

RECENT POSTS

What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10